A4250 for treating progressive familial intrahepatic cholestasis [ID1570]
In development [GID-HST10031] Expected publication date: TBC
Search results
16 results
-
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
In development [GID-HST10032] Expected publication date: TBC
-
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
In development [GID-HST10033] Expected publication date: TBC
-
OTL-200 for treating metachromatic leukodystrophy [ID1666]
In development [GID-HST10028] Expected publication date: TBC
-
Avalglucosidase alfa for treating late-onset glycogen storage disease type II [ID3737]
In development [GID-HST10030] Expected publication date: TBC
-
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
-
Afamelanotide for treating erythropoietic protoporphyria [ID927]
In development [GID-HST10009] Expected publication date: TBC
-
Metreleptin for treating lipodystrophy (ID861)
In development [GID-HST10011] Expected publication date: 13 January 2021
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]
In development [GID-HST10015] Expected publication date: TBC
-
Human alpha1-proteinase inhibitor for treating emphysema ID856
In development [GID-HST10017] Expected publication date: TBC
-
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]
In development [GID-HST10023] Expected publication date: TBC
-
Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]
In development [GID-HST10027] Expected publication date: TBC
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC
-
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
-
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]
In development [GID-HST10026] Expected publication date: 25 March 2021